Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.

Authors

Yuanyuan Shen, Jinnan Wang, Ruimeng Wang, Zhiqiang Liu, Yueyin Pan, Yingying Du, Menghao Dong

Published in

Journal of inflammation research. Volume 19. Pages 625949. Epub Aug 19, 2026.

Abstract

This study aimed to evaluate pre- and intra-treatment peripheral blood inflammatory and cellular indicators as predictors of pathological response to neoadjuvant immunotherapy plus chemotherapy (nICT) in locally advanced esophageal squamous cell carcinoma (ESCC), and their correlation with prognosis.
310 patients with locally advanced ESCC who received nICT plus radical surgery (Jan 2020-Dec 2025) were retrospectively divided into the pathological complete response (pCR) (n=63) and non-pCR (n=247) groups. Blood indicators at baseline, post-cycle 1, and pre-surgery were analyzed. Univariate and multivariate logistic regression identified independent predictors of response. Receiver operating characteristic curves assessed predictive efficacy and recurrence associations.
Overall pCR rate was 20.32% (63/310). Univariate analysis showed baseline (L⁰) and post-cycle 1 (L¹) lymphocyte counts, and preoperative D-dimer (D-dimer²) significantly correlated with pCR (all P<0.05). Multivariate analysis identified L¹ as an independent protective factor (OR=0.308, 95% CI: 0.146-0.652, P=0.002) and D-dimer² as a risk factor (OR=3.842, 95% CI: 1.102-13.386, P=0.035) for pCR. The area under the curve of L¹ was 0.710 (95% CI: 0.635-0.785, P<0.001). Recurrent patients had lower L⁰ and L¹ levels than non-recurrent (P<0.010), and L¹ independently predicted recurrence (OR=3.490, 95% CI: 1.077-11.315, P=0.037).
nICT induces favorable pathological responses in locally advanced ESCC. Post-cycle lymphocyte count was associated with treatment response and recurrence risk, while elevated D-dimer² is associated with poor pathological response. These findings suggest that these biomarkers may hold promise for efficacy evaluation and risk stratification, though prospective validation is required.

PMID:
42634683
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.